USO 24247
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM):SUCCESSOR-2 (CA057008)
Disease Types: Multiple Myeloma
Eligibility Requirements:
• Documented diagnosis of MM that is measurable
• Subject should have received at least 1 prior line of therapy
• Received treatment with lenalidomide and at least 2
cycles of an anti-CD38 mAb
• Achieved MR or better to at least 1 LOT
• Have documented disease progression during or
after last treatment regimen
• ECOG ≤ 2
• Subjects that have received prior treatment with
mezigdomide or carfilzomib are excluded
• Subjects that received allogeneic stem cell transplantation
or autologous stem cell transplantation within 12 weeks
prior to study intervention are excluded
For more information on this trial CLICK HERE .
Available at: